US · PAVM · MEDICAL - DEVICES
PAVmed Inc. (PAVM) intrinsic value and stock valuation
$1.14as of 2026-11-21 · Mkt cap 32.17M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
PAVmed Inc. DCF and intrinsic value
InvestorsCraft values PAVM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PAVM’s statements →
PAVmed Inc. Graham Number
Graham Number: $21.13d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2014–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70K | $3M | $2.45M | $380K | $500K |
| Operating income | -$-21.81M | -$-44.49M | -$-68.8M | -$-91.09M | -$-54.39M |
| Net income | $400K | $39.8M | -$-64.17M | -$-88.98M | -$-50.35M |
| EPSd | $597K | $18.3M | -$-267.38M | -$-444.9M | -$-296.18M |
| Operating cash flow | -$-5.21B | -$-33.55M | -$-52.04M | -$-70.98M | -$-40.59M |
| Capital expenditure | -$-30K | -$-60K | -$-240K | -$-1.54M | -$-1.47M |
| Free cash flow | -$-5.21B | -$-33.61M | -$-52.28M | -$-72.53M | -$-42.06M |
| Total assets | $38.8M | $30.7M | $33.1M | $54M | $87M |
| Total debt | $13.4M | $31.9M | $48.7M | $36.6M | $0.00 |
| Net debt | $11.8M | $30.7M | $29.1M | -$-3.11M | -$-77.26M |
| Total equity | $22.3M | -$-7.03M | -$-24.02M | $10.9M | $79.4M |
| Cash and short-term investments | $1.54M | $1.19M | $19.6M | $42.8M | $79.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $70K | $3M | $2.45M | $380K | $500K |
| Cost of revenue | $320K | $6.04M | $6.42M | $3.61M | $580K |
| Gross profit | -$-250K | -$-3.04M | -$-3.97M | -$-3.24M | -$-90K |
| Research and development expenses | $4.49B | $5.93M | $14.3M | $25.3M | $19.9M |
| Selling, general and administrative expenses | $17.2B | $36.2M | $48.5M | $60.7M | $34.3M |
| Other expenses | -$-21.64B | -$-640K | $2.02M | $1.78M | $150K |
| Operating expenses | $21.6M | $41.4M | $64.8M | $87.9M | $54.3M |
| Cost and expenses | $21.9M | $47.5M | $71.3M | $91.5M | $54.9M |
| Interest income | $30K | $250K | $510K | $170K | $0.00 |
| Interest expense | $20K | $40K | $590K | $1.28M | $0.00 |
| Depreciation and amortization | $100K | $1.2M | $2.93M | $2.46M | $230K |
| Ebitda | -$-2.34M | $29.7M | -$-75.74M | -$-99.5M | -$-55.9M |
| Operating income | -$-21.81M | -$-44.49M | -$-68.8M | -$-91.09M | -$-54.39M |
| Total other income/expenses, net | $19.3M | $72.9M | -$-10.47M | -$-12.15M | -$-1.73M |
| Income before tax | -$-2.47M | $28.4M | -$-79.26M | -$-103.24M | -$-56.13M |
| Income tax expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $400K | $39.8M | -$-64.17M | -$-88.98M | -$-50.35M |
| Weighted average shares outstanding | $670K | $320K | $240K | $200K | $170K |
| Weighted average diluted shares outstanding | $670K | $2.18M | $240K | $200K | $170K |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.54M | $1.19M | $19.6M | $42.8M | $79.3M |
| Net receivables | $10K | $20K | $60K | $20K | $200K |
| Inventory | $240K | $270K | $540K | $260K | $530K |
| Total current assets | $2.56M | $2.16M | $24.5M | $43.9M | $82.6M |
| Property, plant and equipment, net | $2.08M | $2.65M | $6.05M | $5.49M | $1.58M |
| Goodwill and intangible assets | $0.00 | $0.00 | $1.42M | $3.44M | $2.03M |
| Long-term investments | $34.1M | $25.6M | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $36.3M | $28.5M | $8.62M | $10.1M | $4.34M |
| Total assets | $38.8M | $30.7M | $33.1M | $54M | $87M |
| Accounts payable | $680K | $660K | $1.79M | $2.7M | $3.3M |
| Short-term debt | $11.7M | $29.6M | $45.8M | $34.8M | $0.00 |
| Deferred revenue | $0.00 | $656.3M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $14.8M | $35.5M | $54.2M | $41.2M | $7.56M |
| Long-term debt | $1.68M | $2.25M | $2.96M | $1.85M | $0.00 |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.68M | $2.25M | $2.96M | $1.85M | $0.00 |
| Capital lease obligations | $2.25M | $2.76M | $4.53M | $2.99M | $0.00 |
| Total liabilities | $16.5M | $37.7M | $57.1M | $43.1M | $7.56M |
| Common stock | $0.00 | $10K | $10K | $10K | $90K |
| Retained earnings | -$-258.73M | -$-254.97M | -$-294.43M | -$-228.17M | -$-138.91M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $22.3M | -$-7.03M | -$-24.02M | $10.9M | $79.4M |
| Total investments | $34.1M | $25.6M | $0.00 | $3M | $1.99M |
| Total debt | $13.4M | $31.9M | $48.7M | $36.6M | $0.00 |
| Net debt | $11.8M | $30.7M | $29.1M | -$-3.11M | -$-77.26M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-2.47B | $28.4M | -$-79.26M | -$-103.24M | -$-56.13M |
| Depreciation and amortization | $105M | $1.2M | $2.93M | $2.46M | $230K |
| Stock-based compensation | $1.71B | $6.45M | $11.1M | $19.5M | $15M |
| Change in working capital | $100K | $510K | $1.59M | -$-720K | -$-1.57M |
| Accounts receivable | $0.00 | $40K | -$-40K | $180K | -$-200K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $20K | -$-60K | -$-920K | -$-740K | $170K |
| Net cash provided by operating activities | -$-5.21B | -$-33.55M | -$-52.04M | -$-70.98M | -$-40.59M |
| Investments in property, plant and equipment | -$-30K | -$-60K | -$-240K | -$-1.54M | -$-1.47M |
| Acquisitions, net | $0.00 | -$-16.48M | $0.00 | -$-3.2M | -$-2.25M |
| Net cash used for investing activities | -$-31M | -$-16.18M | $760K | -$-4.74M | -$-3.72M |
| Common stock issued | $5.7M | $1.6M | $1.82M | $1.89M | $117M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | -$-370K | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $5.59B | $31.3M | $31.2M | $38.2M | $104.3M |
| Net change in cash | $353M | -$-18.45M | -$-20.11M | -$-37.51M | $60M |
| Cash at end of period | $1.54B | $1.19M | $19.6M | $39.7M | $77.3M |
| Operating cash flow | -$-5.21B | -$-33.55M | -$-52.04M | -$-70.98M | -$-40.59M |
| Capital expenditure | -$-30K | -$-60K | -$-240K | -$-1.54M | -$-1.47M |
| Free cash flow | -$-5.21B | -$-33.61M | -$-52.28M | -$-72.53M | -$-42.06M |
Line items
Line items
Line items
About PAVmed Inc.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
- CEO
- Lishan Aklog
- Employees
- 41
- Beta
- 0.55
Explore
Frequently asked questions
What is the intrinsic value of PAVmed Inc. (PAVM)?
InvestorsCraft does not currently publish an intrinsic value for PAVM. How the IC value is calculated.
Is PAVM undervalued?
InvestorsCraft does not publish an undervaluation signal for PAVM at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.